Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis

Inclusion Criteria: 1. Clinical signs \& symptoms of VVC as Total Severity Score, TSC 4 (range 0-15): * vaginal itching (range 0-3) , * vaginal burning or soreness (range 0-3), * abnormal vaginal discharge (range 0-3), * vulvo/vaginal erythema or oedema (range 0-3), * vulvar excoriation or fissure formation (range 0-3). 2. Direct microscopy (Wet smear) positive for yeast forms (hyphae, pseudohyphae) or budding yeasts 3. Normal vaginal pH (≤4.5) 4. Age: 18 years and older 5. Signed Written Informed Consent to participate in this study. Exclusion Criteria: * Recurrent VVC (4 episodes of VVC in the past 12 months). * Women with other vaginal infections, e.g. bacterial vaginosis, aerobic vaginitis, trichomoniasis, and mixed infections. * Women using oral or vaginal antifungals within 2 weeks prior to enrolment. * Women using any intra-vaginal products, also vaginal douches containing soaps and other anionic, surface-active substances, within 2 weeks prior to enrolment. * Women using any antibiotic or anti-infective within 2 weeks prior to enrolment. * Women having menstruation bleeding at enrolment * Cervicitis, cervical erosions, and malignant tumours in the genital tract * Pregnancy or lactation. * Women not consenting to be sexually abstinent during the treatment, not taking oral contraceptive or not having an IUD for contraception * Woman using intravaginal pessaries, rings, sponges or diaphragms * Severe systemic diseases (diabetes mellitus, cancer, tuberculosis, autoimmune diseases, severe psychiatric conditions, etc.). * Women with confirmed or suspected STD (HIV infection, gonorrhoea, syphilis, chlamydiasis, etc.). * Known or suspected hypersensitivity to one of the study medications, inclusive their excipients. * Participation of patient in another clinical study concomitantly or within 30 days prior to enrolment * Patient is relative of, or staff directly reporting to, the investigator.